Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 Jul 14;21(12):2115–2122. doi: 10.1016/j.bbmt.2015.07.012

Figure 1. Overall outcomes of non-myeloablative, related-donor bone marrow transplantation with posttransplantation high-dose cyclophosphamide and rituximab (n=83).

Figure 1

A) Relapse and non-relapse mortality by competing risk analysis. B) Acute graft-versus-host disease (grades 2–4 and grades 3–4) by competing risk analysis. C) Chronic graft-versus-host disease (overall and requiring systemic therapy) by competing risk analysis. D) Progression-free and overall survival. Of these 83 patients, 69 received HLA-haploidentical grafts.